Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

Ayoade Joy Ademuyewo says that anesthesiology is “the coolest thing in the world.” That’s why she became a certified registered nurse anesthetist.

And that career, which she says is “the perfect blend of science and art,” led to the creation of her startup, Lokum.

Lokum App is a matchmaking engine that aims to connect Ademuyewo’s peers with jobs. She explains that before her innovation, staffing for nurse anesthetists traditionally owed to job boards 30 years older than she was or to recruitment agencies that left them at a disadvantage.

“I didn't want to use that job board because it was sort of difficult to use and I didn't want to use it and a lot of other people felt the same way,” she recalls.

When a desperate friend asked for her help navigating the terrain of finding CRNA work as an independent contractor, Ademuyewo says the wheels began turning in her mind.

“I just thought, 'Why can't I open up my phone and see all of the available jobs to me, based on my preferences and my skills? And I can easily select from them to go to my next job.' And that's sort of where the questions started. And I just kept asking those questions. And I think about two or three years into asking the questions I was like, 'Oh my gosh, I think I'm starting a company,'” Ademuyewo says.

In the hours that she wasn’t in surgery, the CRNA began doing market research.

“As I was studying the market, and mapping it out, these really complex mind maps started to happen. And it was almost a natural conclusion that the more you understand the problem, the more the solution starts to appear to you,” she explains.

And she saw that the obvious solution was also potentially a big opportunity for her to create something entirely new — neither a job board nor an agency, but something entirely new. Ademuyewo calls Lokum a “matchmaking engine.” It takes the preferences, specialties and skills of CRNAs like her and matches them to jobs that make sense for them. To date, the pilot has connected users with around 200 hospitals and clinics in 20 states.

Fortunately, because there are so few CRNAs in practice, they are a unified bunch.

“It’s a really well-networked profession,” says Ademuyewo. “ I'm lucky to be in a profession where what we do is really special and really specialized.”

Because she was already part of the tight knit community, the founder had no trouble finding pilot customers. She worked with Houston-based Octaria Software to engineer the technical side of the app, as well as another local cybersecurity firm to work on infrastructure.

Lots of big news has come for Ademuyewo in the first half of 2024. She participated in this year’s cohort of the Google for Startups Accelerator Program-North America, which she says helped to gain traction in her fundraising amid a bear market.

The result? Early this month, Lokum announced a raise of $700,000 in pre-seed funding, which will be allocated to improving and enhancing the existing technology. Those funds came from Houston investors including Aileen Allen, of the Houston Angel Network, Mercury, and The Artemis Fund; and Matt Miller, former Liongard product executive, as well as from Houston-based VC firm South Loop Ventures. More came from the non-local JP Morgan and Techstars.

Today, Ademuyewo is devoted full-time to Lokum, though she still practices her favorite combination of science and art on weekends in order to maintain her licensure.

“I will always be clinical, that will never change,” she says. “Part of that is just staying close to the problem and the people who are experiencing it, I think that is exactly the right thing for me to be doing.”

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

Houston innovator raises pre-seed funding for health care staffing platform

just closed

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission.

"I'm incredibly proud to have earned the trust of my colleagues, investors, team, and mentors in solving this complex problem."

Ademuyewo raised the round with support from local investors, including Aileen Allen, an adviser and investor associated with the Houston Angel Network, Mercury, and The Artemis Fund; and Matt Miller, former Liongard product executive, as well as from Houston-based VC firm South Loop Ventures. Techstars and JP Morgan also contributed to the round.

"Lokum has found a way to disrupt an organically inefficient and expensive market with an elegant solution that doesn't just save hospitals time and money, but also increases the pool of specialty providers in a market that is consistently strapped for such expertise," Jerry Varnado, venture partner at South Loop Ventures, adds. "This is what disruption in healthcare looks like — scalable commercial solutions that contribute towards better patient care, and we're happy to be part of Lokum's journey."

Ademuyewo has the idea to start Lokum after her experience as an independent contract nurse anesthetist amid the height of the pandemic as she witnessed third-party recruitment agencies take advantage of medical professionals like herself.

Now, the platform's early pilot, which focuses on clinicians in anesthesiology, has served clients across nearly 200 hospitals and surgery centers in 20 states. Ademuyewo also participated in 2024’s cohort for the Google for Startups Accelerator Program-North America, where she spent 10 weeks developing and building her company and platform.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.